Drug intelligence / Profile preview

Equiplas-E

Development stage: Unknown
Lead developer: Plasvacc Holdings
Administration: Oral, Intravenous

Overview

Equiplas-E is a veterinary biopharmaceutical product, likely a serum-derived or hyperimmune plasma product, developed by Plasvacc Holdings. It is intended for use in animals such as horses, dogs, and cattle. The product was part of a portfolio that Bioniche Life Sciences intended to acquire in 2011, but the acquisition was terminated.

Beyond the preview

Go deeper on Equiplas-E.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Equiplas-E.

Explore the full profile